NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Thursday that its second quarter revenues were essentially flat year over year at $324,000 versus $323,000 in Q2 2013.

The company posted product revenue of $211,000, flat with $210,000 in Q2 2013. That revenue was based on 4,223 OVA1 ovarian cancer tests performed in Q2 2014 versus 4,184 tests performed in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.